Understanding the progression and prognosis of Moyamoya disease
Official title: Imaging Investigation on the Evolution and Prognosis of Moyamoya Disease
Run by Chinese PLA General Hospital · NCT05619068 · Data updated 2026-11-12
This study is trying to see how Moyamoya disease affects brain images and thinking skills over time to help improve diagnosis and treatment for patients.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 10 Years to 60 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Chinese PLA General Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | September 1, 2022 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | December 21, 2022 |
| Trial ID | NCT05619068 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 10 to 60 diagnosed with Moyamoya disease who meet specific imaging criteria.
✕Probably not a fit
Patients with severe cerebral infarction or those unable to cooperate for cognitive assessments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to investigate the evolution of imaging appearances and cognitive function in patients with Moyamoya disease (MMD). It seeks to establish a prognosis evaluation system based on imaging biomarkers, which may enhance the diagnosis and pretreatment assessment of MMD. The study will also explore changes in cognitive function during follow-up or after revascularization, providing insights into the effects of cerebral perfusion on cognitive abilities. By utilizing new imaging methods and clinical approaches, the research intends to contribute significantly to the management guidelines for MMD.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for patients with Moyamoya disease.
How similar studies have gone: While there have been studies on Moyamoya disease, this approach focusing on imaging biomarkers and cognitive function is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with MMD: Conventional angiography or MRI examination conforms to the Guidelines for Diagnosis and Treatment of MMD (Neurol Med Chir (Tokyo) 52, 245-266, 2012), It is characterized by stenosis or occlusion of the end of the internal carotid artery, anterior cerebral artery and/or the beginning of the middle cerebral artery of unknown cause, accompanied by dilatation of the perforating artery at the base of the brain or of capillaries on the surface of the brain, i.e., the formation of smoke vessels. Sign the informed consent. Older than 10 and younger than 60. The education level of patients reached primary school or above (years of education ≥6). Exclusion Criteria: * Patients with massive cerebral infarction, multiple paraventricular ischemic foci, or significantly enlarged ventricular hydrocephalus after intracerebral hemorrhage. Patients with vascular diseases caused by immune system disease. Patients can not cooperate to complete the cognitive function test. There are other neuropsychiatric diseases that affect cognitive function (such as Alzheimer's disease, Parkinson's disease, depression, anxiety disorder, cerebral hemorrhage, hydrocephalus, craniocerebral trauma, etc.). Patients with contraindications of magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies) or unable to complete image collection.
Where it's running
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Jinhao Lyu
- Email: 330322990@qq.com
- Phone: +8615903562929
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Risk prediction for stroke and cognitive decline in Moyamoya disease and Moyamoya syndrome
A large multicenter study tests whether combining clinical data, imaging, lab and genetic information can predict who will have stroke or cognitive decline among people with Moyamoya.
-
Biomarkers That Signal Silent Strokes in High-Risk Cardiac Procedures
This study tests whether blood biomarkers NSE and NFLs can predict silent brain injuries and later cognitive problems in adults having high-risk transcatheter heart procedures.
-
Blood-based tests and digital cognitive checks to help triage dementia
This study tests whether adding blood biomarkers, APOE4 genetic info, and digital cognitive tests can help dementia diagnosis be faster in NHS Memory Clinics.
-
Cardiovascular and Cognitive Health Initiative
This study tests whether targeted cognitive and heart-health interventions can help improve thinking skills in adults with cardiovascular disease.
-
Synbiotic blend of LA-5 and agave inulin for mild cognitive impairment
This pilot crossover study tests whether a synbiotic containing Lactobacillus acidophilus LA-5 and agave inulin can help adults aged 60–75 with mild cognitive impairment.
-
5T MRI and Metabolomics to Predict Hemorrhage Risk in Moyamoya Disease
This study tests whether advanced 5T MRI imaging and metabolomics can help predict which moyamoya patients are at higher risk of intracranial hemorrhage.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.